HebeCell
HebeCell is a pre-clinical biotechnology company developing off-the-shelf allogeneic natural killer (NK) cell therapies using a proprietary 3D-iPSC platform for cancer immunotherapy and other diseases, headquartered in Natick, Massachusetts.
- Company typePrivate
- Founded2016
- HeadquartersNatick, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What HebeCell does
HebeCell is a privately held, pre-clinical biotechnology company founded in 2016 and based in Natick, Massachusetts, that develops off-the-shelf allogeneic natural killer (NK) cell therapies for cancer immunotherapy and other diseases. The company's core offering is a proprietary 3D-iPSC (three-dimensional induced pluripotent stem cell) platform that enables scalable, consistent production of NK cells from iPSCs, addressing the manufacturing and accessibility limitations inherent to patient-specific autologous cell therapies. The platform is positioned to serve cancer patients requiring immunotherapy, including those with hematological malignancies and solid tumors, with potential applicability to other disease areas.
The company's business model is currently non-commercial: as a development-stage biotech, HebeCell generates no product revenue and has no publicly disclosed pricing structure. Its go-to-market posture is defined by R&D progression and strategic partnering rather than direct sales. In August 2021, Jacobio Pharmaceuticals made a $53 million strategic investment and entered a co-development partnership to advance the 3D-iPSC NK cell pipeline, with the deal including leadership changes. This followed an earlier $10 million round led by Aceso Biotech Venture Fund in April 2020, bringing cumulative disclosed funding to approximately $63 million.
HebeCell operates in a competitive landscape alongside roughly a dozen other developers pursuing iPSC-derived NK cell therapies, including named peers such as Century Therapeutics and Fate Therapeutics. The company employs between 11 and 50 people, led by founder and Chief Scientific Officer Allen Feng, President and CEO John Lu, VP of Finance and Administration Lily Tang, and VP of Regulatory Affairs and Quality Assurance Edmund Mickunas. No clinical trial initiations, IND filings, regulatory designations, or product approvals are disclosed in available sources, placing HebeCell firmly in the preclinical development phase with commercialization dependent on successful platform translation into clinical-stage assets.
HebeCell firmographics
Firmographics- Name
- HebeCell
- Legal name
- Hebecell
- Website
- https://hebecellcorp.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HebeCell is a pre-clinical biotechnology company developing off-the-shelf allogeneic natural killer (NK) cell therapies using a proprietary 3D-iPSC platform for cancer immunotherapy and other diseases, headquartered in Natick, Massachusetts.
- Ownership category
- akta.pro rank
HebeCell industry classification
Industry- Product category
- Cell Therapy / Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- NK Cell TherapiesStem Cell Therapies (MSC/iPSC/HSC-derived)Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Keywords
Where HebeCell is headquartered
LocationHeadquarters
- HQ city
- Natick
- HQ country
- United States
- HQ region
- North America
Markets served
HebeCell business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Marketing channels2 records
HebeCell product offering
Product offeringCore offering
HebeCell develops and commercializes cell-based therapeutics using its proprietary 3D-iPSC platform to manufacture off-the-shelf allogeneic natural killer (NK) cell therapies. The company's products target cancer immunotherapy indications, including hematological malignancies and solid tumors, and may extend to other diseases. HebeCell is pre-commercial, with therapies currently in development through pharmaceutical partnerships such as Jacobio Pharmaceuticals.
Product overview
HebeCell offers a proprietary 3D-iPSC platform for developing off-the-shelf natural killer (NK) cell therapies. The platform enables scalable production of iPSC-derived NK cells for cancer immunotherapy and potential treatment of other diseases. The company's core technology differentiates itself through a 3D culture system for iPSC expansion and differentiation into NK cells.
Differentiator
Problem solved
Functional benefit
Products and services
- 3D-iPSC Platform
Companies that use HebeCell
Customer profileSegments1 record
Ideal customer profiles2 records
HebeCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
HebeCell partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Jacobio PharmaceuticalscoreJacobio Pharmaceuticals announced a strategic investment in Hebecell to develop iPSC-NK cell therapy, expanding their pipeline into cell-based treatments for cancer and other diseases. The collaboration focuses on off-the-shelf natural killer cell therapies using Hebecell's proprietary 3D-iPSC platform. The deal includes leadership changes and aims to advance clinical and commercial applications of the therapy.
Recent moves4 records
Expansion highlights4 records
HebeCell competitors and assessment
Company assessmentDirect peers
- Fate Therapeutics: Clinical-stage pioneer of iPSC-derived NK and T-cell therapies with a proprietary iPSC platform for off-the-shelf cancer cell therapies. Directly comparable to HebeCell in modality (iPSC-derived immune cells) and target indications, with substantially more advanced clinical assets.
- Century Therapeutics: Develops iPSC-derived allogeneic NK and T-cell therapies for cancer using engineered iPSC platforms. Competes in the same iPSC-derived immune cell therapy category as HebeCell and serves overlapping oncology indications.
- Nkarta Therapeutics: Clinical-stage developer of off-the-shelf allogeneic NK cell therapies for cancer, including CAR-NK programs. Closely comparable to HebeCell on modality (allogeneic NK cells) and oncology focus.
- Shoreline Biosciences: Develops iPSC-derived allogeneic NK cell therapies and has established partnerships with major pharma. Operates in the same iPSC-NK modality space as HebeCell with a similar allogeneic, off-the-shelf positioning.
- Cytovia Therapeutics: Clinical-stage biotech developing NK cell therapies including iPSC-derived and gene-edited NK cells for cancer and viral diseases. Directly comparable to HebeCell in modality and indication strategy.
Broad incumbents
- Allogene Therapeutics: Leading allogeneic CAR-T cell therapy developer with multiple clinical programs. Competes in the broader allogeneic cell therapy market HebeCell targets, though focused on T-cells rather than NK cells.
- Caribou Biosciences: Clinical-stage cell and gene therapy company leveraging CRISPR-based allogeneic CAR-NK and CAR-T platforms. Overlaps with HebeCell on allogeneic NK cell therapy for oncology and uses similar iPSC- and genome-editing-enabled approaches.
- Cellectis: Clinical-stage gene-editing company developing allogeneic CAR-T and has expanded into NK-cell-based therapies. A broader incumbent in engineered cell therapy with technology overlap to HebeCell's platform thesis.
Emerging players
- Dragonfly Therapeutics: Developer of NK cell engager therapies and other immune-modulating modalities for cancer and autoimmune disease. Comparable to HebeCell in NK-based therapeutic strategy, though using engager molecules rather than cell therapy.
- Glycostem Therapeutics: Clinical-stage developer of off-the-shelf NK cell therapies (oNKord) derived from cord blood. A smaller allogeneic NK cell competitor with similar off-the-shelf positioning to HebeCell's pipeline.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
HebeCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
HebeCell leadership team
Management profileNumber of profiles
Profiles4 records
HebeCell funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HebeCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HebeCell
What does HebeCell do?
HebeCell develops and commercializes cell-based therapeutics using its proprietary 3D-iPSC platform to manufacture off-the-shelf allogeneic natural killer (NK) cell therapies. The company's products target cancer immunotherapy indications, including hematological malignancies and solid tumors, and may extend to other diseases. HebeCell is pre-commercial, with therapies currently in development through pharmaceutical partnerships such as Jacobio Pharmaceuticals.
Is HebeCell a public or private company?
HebeCell is a private company. It is classified as venture growth investor backed and is currently operating.
When was HebeCell founded?
HebeCell was founded in 2016. It employs 11 to 50 people.
Where is HebeCell based?
HebeCell is headquartered in Natick, United States, in the North America region.
Who are HebeCell's main competitors?
Direct peers on record are Fate Therapeutics, Century Therapeutics, Nkarta Therapeutics, Shoreline Biosciences and Cytovia Therapeutics. Broad incumbents are Allogene Therapeutics, Caribou Biosciences and Cellectis. Emerging players are Dragonfly Therapeutics and Glycostem Therapeutics.
Does HebeCell have an API?
No public API is recorded for HebeCell.
What industry is HebeCell in?
HebeCell's product category is Cell Therapy / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.